Biosyntia Completes US$1.9M Funding

biosyntiaBiosyntia ApS, a Denmark-based biotech company that develops processes for biological production of vitamins, completed a Danish KR12.5m (approx. US$1.9m) funding round.

The round was led by Novo Seeds. In conjunction with the funding, Søren Carlsen, Managing Partner of Novo Ventures and Novo Seeds, and Søren Møller, Managing Investment Director Novo Seeds, will join the Board of Biosyntia.

Led by technology co-inventor Hans Genee, Morten Sommer, and Henrik Dalbøge, Chairman, Biosyntia is a biotech startup developing processes for biological production of vitamins by applying its synthetic biology and metabolic engineering platform. The company develops biocatalysts by employing patent pending high-throughput screening technology. Its first focus area is bio-based production of vitamins for the food and feed industry.

In conjunction with the financing, Biosyntia has also entered into a collaboration with the Center for Biosustainability, at The Technical University of Denmark to gain access to complementary cell factory development technologies.





Join the discussion